The purpose of the research is to compare brain activity and structure, as well as immune‑related blood findings, between people with ongoing symptoms and those who have recovered fully. Participants will have a brief blood draw, undergo a scan that measures cellular energy use using PET, and receive a detailed brain scan with MRI that shows both structure and function. After the imaging sessions, individuals will complete questionnaires about the presence and severity of their symptoms. The study follows a straightforward schedule of these visits over several weeks, without any additional experimental treatments.

The study is for people whose cancer has gotten worse after treatment with platinum-based chemotherapy and anti-PD-L1 or anti-PD-1 therapy, which are treatments that help the immune system fight cancer. Treatment of physician’s choice may include topotecan, tisotumab vedotin, irinotecan, pemetrexed, gemcitabine, or vinorelbine, and some medicines may be given with supportive care such as paracetamol, H2-receptor antagonists, and glucocorticoids to help reduce side effects. The study is randomized, which means treatment is assigned by chance, and it is open-label, which means both the study team and the participant know which treatment is being given.

The study has an initial part and then a larger comparison part. In the first part, MK-2870 is given to gather early information about how it acts in the body and how well it is tolerated. In the main part, MK-2870 is compared with other available cancer treatments. Treatment is given over time, with regular study visits and checks for side effects and general health while the cancer is being followed.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

In the study, treatment is given before surgery, and then the planned surgery is performed if possible. During the study, there are regular checkups, blood tests, and other routine medical exams to watch for side effects and to see how the disease is responding. After surgery, follow-up continues for a period of time to look for any return of the cancer and to monitor overall health.

Durvalumab is a type of medicine that helps the immune system attack cancer cells. The chemotherapy used with it is ddMVAC, a group of cancer medicines that are commonly given together for bladder cancer. The study is open-label, which means both the medical team and the participant know which treatment is being given.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The study is testing whether adding the experimental oral drug pelabresib (code name DAK539) to the approved oral medication ruxolitinib improves reduction of spleen size and relief of symptoms compared with taking ruxolitinib together with a placebo. The purpose of the study is to determine if the combination therapy provides a greater benefit than the standard treatment alone.

Participants will take the study tablets each day for several months. Throughout the trial they will undergo imaging tests, such as MRI or CT scan, to measure the size of the spleen, and they will complete simple questionnaires about how they feel. Regular health checks will be performed to monitor safety, and the study will continue for about a year to observe how the treatment works over time.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

The purpose of the study is to learn how well the new medicine works against the cancer and how safe it is for patients, both by itself and when combined with the other drug. Participants will attend regular visits where they receive the infusion in a series of treatment cycles, and doctors will check for any side effects and whether the cancer is responding.

Throughout the study, doctors will monitor participants for common side effects, track any changes in the size of the cancer, and take blood samples to understand how the medicine moves through the body. The overall goal is to find a dose that is effective while keeping side effects manageable.

People in the study are assigned by chance to receive different doses of ELV001 or placebo tablets. The study is double-blind, which means that the treatment given is not known to the participants or the study team during the study. Treatment is taken for a period of time, and the health of the joints and overall condition are checked during the study visits. Safety is also watched closely, including possible side effects and changes in heart tracing, blood tests, and vital signs.

The study is looking at whether ELV001 can improve signs and symptoms of active rheumatoid arthritis when added to standard treatment. It also compares different dose levels to see how they work and how well they are tolerated.

Participants are assigned to one of the study treatments and receive injections over time during regular study visits. The study team follows how the cancer responds and watches for side effects and other health changes. It also looks at how long the treatment effects last and how the treatments affect daily well-being and symptoms.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The research is divided into different parts. In Part A, researchers study how safe the medication is and how well patients tolerate it. In Part B, they examine how effective the medication is at stopping tumor growth. Some patients will receive AL102, while others will receive a placebo. The study also includes an extended treatment period where all participants can receive the active medication.

Throughout the study, doctors will monitor the size of tumors using medical imaging. They will also track any changes in symptoms and how patients feel while taking the medication. The medication is being tested at different dose levels to find the most effective and safe amount for treating desmoid tumors.

The purpose of the trial is to find out how well tarlatamab can shrink or control the brain tumors. Participants will receive the medication on a regular schedule, and doctors will look at the brain with MRI scans after six weeks and then every six weeks, while chest and abdominal areas will be examined with CT scans at the same intervals. The study follows patients for several months to observe both short‑term and longer‑term effects.

At each clinic visit, safety checks are performed and any side effects are recorded, and the overall participation period may extend up to about a year, depending on continued treatment and follow‑up imaging.

The purpose of this study is to test the safety of ALE.P03 and find the right dose to use, and then to see how well it works against these types of cancer. The study is divided into two main parts called Phase 1 and Phase 2. In Phase 1, different doses of the medication will be tested in small groups of patients to see which dose is safest and best tolerated. During this part, doctors will carefully watch for any side effects and check how the body handles the medication. In Phase 2, the chosen dose will be given to a larger group of patients to see how well the medication works at shrinking or controlling the cancer.

Patients joining this study must have already received standard treatments for their cancer, which may have included chemotherapy, certain antibodies that help the immune system fight cancer, and other medications depending on the type of cancer. The study requires a sample of tumor tissue to be tested in a laboratory to confirm that the CLDN1 protein is present at high enough levels. During the study, patients will have regular check-ups that include blood tests, physical examinations, heart monitoring using ECG, and scans to measure the size of the tumors. The doctors will track any side effects, measure how much medication is in the blood over time, and check whether the body develops an immune response to the medication. The study will continue until 2029.

The purpose of this study is to investigate whether CBD is effective in reducing irritability and other behavioral problems in children and adults with these three conditions. The study will look at how CBD affects various aspects of behavior, including symptom severity, quality of life, anxiety, depression, mood, autism symptoms, sensory processing, parental stress, and personal goals. For those who also experience seizures, the study will track seizure frequency. The safety of the treatment will be monitored by recording any side effects and checking liver enzyme levels throughout the study.

The study uses a special design called an N-of-1 series, which means each participant will be studied individually over time. Participants will take the CBD oral solution for up to 24 weeks while maintaining their current medications and treatments stable. During this time, caregivers will complete questionnaires and keep diaries to track behavioral changes and any seizures that occur. The maximum daily dose of CBD will be 25 milligrams per kilogram of body weight. Participants need to be at least 6 years old and must have a caregiver who can provide regular reports about their behavior and well-being.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this research is to determine if this treatment is both safe and effective for patients with this specific type of kidney cancer. During the study, participants will receive the medication directly into their renal pelvis (the part of the kidney that collects urine). The treatment will be monitored over time to see how well it works in treating the cancer.

This is a single-arm, open-label study, which means all participants will receive the same treatment, and there is no comparison group. The study will track how patients respond to the treatment over an extended period, with particular attention paid to any changes in their cancer status and any side effects that may occur. Participants will be followed for at least 18 months after receiving their first dose of the medication.

During the study, participants receive flutemetamol (18F) and then undergo a PET scan, which is an imaging test that shows where the tracer goes in the body. Some participants may also have a MRI scan, which uses magnetic fields to create pictures of the brain. Blood samples and symptom questionnaires are also used to gather more information about the amount of microclots and the presence and severity of symptoms.

The study is expected to run over several months. It focuses on whether this imaging method can show differences in amyloid-containing microclots between people with post-COVID syndrome and controls, and whether these findings relate to symptoms and brain scan results.

The purpose of the study is to evaluate PFS at 12 months compared with historical results. After the first infusion, patients return for regular treatment sessions over several months while doctors monitor the cancer for any signs of growth or spread, record any side effects that are related to the immune system, and assess overall well‑being. PFS means the length of time a person lives without the disease getting worse. Immune‑related side effects are reactions that happen because the treatment activates the body’s own defenses, and quality of life refers to how a person feels and functions during the study.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to determine whether this cell‑based therapy can improve how long patients live without the disease getting worse and ultimately increase overall survival. After the chemotherapy course, the cell infusion is administered, followed by surgery to remove the tumor when possible. Patients are then monitored over time to see if the cancer returns, using imaging criteria called RECIST 1.1, and to assess quality of life and safety. The follow‑up period includes regular doctor visits, scans, and blood tests to track the immune response and any side effects.

People in the study are assigned by chance to receive either RO7795068 or placebo, and neither the participants nor the study team know which one is being given. The study lasts for about 72 weeks. During this time, the treatment is given regularly, and the study team checks body weight, general health, and possible side effects. The study also looks at changes in waist size, blood sugar, blood fats, blood pressure, eating habits, and quality of life.

Possible side effects, changes in blood tests, heart tracing results, and other safety checks are monitored throughout the study. The trial is designed to find out whether RO7795068 can help with weight management in adults with obesity or overweight who do not have type 2 diabetes.

The purpose of this study is to find out whether the study medications are better than placebo at reducing the occurrence of major liver-related complications. During the study, researchers will monitor participants for various liver problems including progression to cirrhosis (severe liver scarring), development of complications like varices (enlarged veins in the digestive tract), ascites (fluid buildup in the abdomen), hepatic encephalopathy (brain function problems caused by liver disease), and other serious liver conditions. The study will also track whether participants need liver transplantation or experience other serious outcomes.

Participants in this study will receive their assigned treatment over an extended period while being regularly monitored by the study team. The study requires participants to have evidence of liver fat confirmed by MRI (a type of imaging scan) and liver scarring confirmed through non-invasive tests, though a liver biopsy is not required to join the study. Throughout the study, participants will have regular check-ups and assessments to evaluate how well the treatment is working and to monitor their liver health and overall wellbeing.

People in the study are assigned by chance to one of the eye drop groups. The study lasts for several weeks, and the eye is checked during treatment and again afterward to see whether healing has been maintained. The main focus is whether the damaged eye surface closes and stays healed over time.